DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0124574 A1 Lockw00d Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0124574 A1 Lockw00d Et Al US 200901 24574A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0124574 A1 LOckW00d et al. (43) Pub. Date: May 14, 2009 (54) CAROTENOIDANALOGS AND DERIVATIVES A63L/365 (2006.01) FOR THE PREVENTION OF PLATELET A6II 3/66 (2006.01) AGGREGATION A613/60 (2006.01) A 6LX 3L/727 (2006.01) (76) Inventors: Samuel F. Lockwood, Lake A63L/366 (2006.01) Linden, MI (US); R. Preston A63L/4365 (2006.01) Mason, Manchester, MA (US) (52) U.S. Cl. ........... 514/56; 514/547: 514/483; 514/479; Correspondence Address: 514/473; 514/136; 514/163; 514/460; 514/301 MEYERTONS, HOOD, KIVLIN, KOWERT & (57) ABSTRACT GOETZEL, P.C. P.O. BOX 398 The presently described embodiments are directed to compo AUSTIN, TX 78767-0398 (US) sitions that include one or more carotenoid analogs or deriva tives for use in the treatment of a disorder associated with (21) Appl. No.: 12/079,253 platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing (22) Filed: Mar. 24, 2008 compositions suitable for use in Such treatments. Further embodiments provide for pharmaceutical compositions that Related U.S. Application Data include one or more carotenoid analogs or derivatives in (60) Provisional application No. 60/919,637, filed on Mar. R with St. E. still Ein or 23, 2007, provisional application No. 60/948,787, medicaments suitable Ior une treatment of a disorder associ filed on Jul. 10, 2007. ated with platelet aggregation. Yet farther embodiments pro s vide for methods of treating a disorder associated with plate O O let aggregation that include administering to a Subiect who Publication Classification E. from Such treatment Nitti . (51) Int. Cl. tions suitable for inhibiting platelet aggregation in a subject A6 IK 3L/225 (2006.01) undergoing said treatments, and that include carotenoidana A6IP 7/02 (2006.01) logs or derivatives, optionally in combination with one or A6 IK3I/27 (2006.01) more additional antiplatelet agents. Patent Application Publication May 14, 2009 Sheet 1 of 21 US 2009/O124574 A1 FIG. 1A FIG. 1B FIG 1C Welston gold Wire 6pm nano Sensor (tip 200 um) Endothelial cell w w reserver - 7 - 8 um ruler mirror." Patent Application Publication May 14, 2009 Sheet 2 of 21 US 2009/0124574 A1 A 25 20 15 O Control Astaxanthin Clopidogrel AstaXanthin -- Clopidogrel 3 O O 2 5 O 2 O O 150 100 50 Astaxanthin Clopidogrel AStaxanthin -- Clopidogrel FIG. 3 Patent Application Publication May 14, 2009 Sheet 3 of 21 US 2009/O124574 A1 <!--------------------------?--> 009Z 09ZZ 000Z 09/,?. 009|| 097|| 000|| 09/ 009 09% uOle Juego UOO ON Patent Application Publication May 14, 2009 Sheet 4 of 21 US 2009/0124574 A1 7OO KXX& x: 8 COLO OO CDC 388 &K 400çOQN!<- |- . OCDOOOO Control Astaxanth n Clopidogrel Astaxanthin -- Clopidogrel FIG. 5 Control Astaxanth r Clopidogrel Astaxanthin r Clopidogrel FIG. 6 Patent Application Publication May 14, 2009 Sheet 5 of 21 US 2009/0124574 A1 CN LO Control Astaxanthin Clopidogrel Astaxanthin -- Clopidogrel FIG. 7 Patent Application Publication May 14, 2009 Sheet 8 of 21 US 2009/O124574 A1 2500 5 c 2OOO O. N w 1500 X O Zas 1 OOO 8 500 o d Control Astaxanthin Aspirin Simvastatin 500 400 200 1OO Control AStaxanthin Aspirin Simvastatin FIG. 12 Patent Application Publication May 14, 2009 Sheet 9 of 21 US 2009/0124574 A1 500 400 300 200 1OO Control Aspirin Aspirin Aspirin Aspirin Aspirin -- -- H H AstaX AstaX AS tax Astax 0.1 uM 1.0 uM 5.0 uM 10.0 uM FIG. 13 4500 4000 3500 3000 2500 2000 1500 1 OOO 500 Control Aspirin Aspirin Aspirin Aspirin Aspirin Ha H Astax Astax AstaX AStax 0.1 uM 1.0 uM 5.0 uM 10.0 M FIG. 14 Patent Application Publication May 14, 2009 Sheet 10 of 21 US 2009/O124574 A1 375 T 300 225 - - 150 - Control Simva Simva Simva Simva Sinva s -- -- -- Astax Astax As tax AstaX 0.1 puM 1.0 uM 5.0 puM 10.0 uV FIG. 15 3500 3OOO 2500 2000 1500 1000 500 Control Simva Simva Simva Simva Simva -- -- -- Astax AstaX Astax Astax 0.1 uM 1.0 uM 5.0 uM 10.0 uM FIG. 16 Patent Application Publication May 14, 2009 Sheet 11 of 21 US 2009/0124574 A1 14 1 2 1 O 6 Control Aspirin Aspirin Aspirin Aspirin Aspirin H -- -- -- Astax AStax AStax AStax 0.1 uv 1.0 uM 5.0 uM 10.0 uM FIG. 17 Control Simva Simva Simva Simva Simva -- -- -- AstaX AStax AStax Astax 0.1 uM 1.0 uM 5.0 uM 10.0 uM FIG. 18 Patent Application Publication May 14, 2009 Sheet 12 of 21 US 2009/O124574 A1 Control Astaxanthin Aspirin Simvastatin FIG. 19 Patent Application Publication May 14, 2009 Sheet 13 of 21 US 2009/0124574 A1 Oz'91-' Patent Application Publication May 14, 2009 Sheet 14 of 21 US 2009/0124574 A1 Astaxanthin in Rat Plasma. 4 Hours. After Ingestion of Astaxanthin 50 40 30 20 10 O -10 Astaxanthin in Rat Plasma: 4 Hours. After ingestion of ADS -a CC YwE Gy d CS d h C c O CC Astaxanthin in Rat Plasma. 4 Hours. After Ingestion of ADL FIG 21 Patent Application Publication May 14, 2009 Sheet 15 of 21 US 2009/0124574 A1 Astaxanthin in Rat Plasma: 8 Hours. After Ingestion of Astaxanthin 50 40 30 Astaxanthin in Rat Plasma. 8 Hours. After ingestion of ADS 50 40 an ag 30 Ye'8 d O - C O a. Astaxanthin in Rat Plasma. 8 Hours. After Ingestion of ADL 50 40 30 2O 10 O -10 FIG 21 (Continued) Patent Application Publication May 14, 2009 Sheet 16 of 21 US 2009/O124574 A1 ZOZZOy?dXO–Kpn?SXAd Patent Application Publication May 14, 2009 Sheet 17 of 21 US 2009/O124574 A1 Patent Application Publication May 14, 2009 Sheet 18 of 21 US 2009/0124574 A1 m Patent Application Publication May 14, 2009 Sheet 19 of 21 US 2009/O124574 A1 Patent Application Publication May 14, 2009 Sheet 20 of 21 US 2009/O124574 A1 90710yIdxo–Ápn?SXd Patent Application Publication May 14, 2009 Sheet 21 of 21 US 2009/O124574 A1 ZOGLOMdXO–Ápn}SXAd US 2009/O124574 A1 May 14, 2009 CAROTENOID ANALOGS AND DERVATIVES granular contents of platelets Supply additional adhesion mol FOR THE PREVENTION OF PLATELET ecules, growth factors, coagulation enzymes and other spe AGGREGATION cialized molecules instrumental in the process of thrombus formation and the initiation of the healing process. PRIORITY CLAIM 0008. In addition to coronary artery disease/myocardial 0001. This application claims the benefit of priority under infarction, cerebrovascular disease and peripheral vascular 35 U.S.C. 119 (d)(e) to Provisional Patent Application Ser. disease, diseases and disorders associated with inappropriate No. 60/919,637, entitled “CAROTENOIDANALOGS AND platelet activity and arterial thrombosis also include, for DERIVATIVES FOR THE INHIBITION OF AGGREGA example, stable and unstable angina, transient ischemic TION' filed Mar. 23, 2007 and to Provisional Patent Appli attacks, placental insufficiency, unwanted thromboses Subse cation Ser. No. 60/948,787, entitled “CAROTENOIDANA quent to Surgical procedures (e.g., aortocoronary bypass Sur LOGS AND DERIVATIVES FOR THE PREVENTION OF gery, angioplasty and stent placement, and heart Valve PLATELET AGGREGATION filed Jul. 10, 2007. The replacement), or thromboses Subsequent to atrial fibrillation. above-cited applications are commonly assigned with the Inhibitors of platelet activity can provide therapeutic and present invention, and the entire contents thereof are incor preventive benefits for each of these diseases or disorders. It porated by reference as though fully set forth herein. is also possible that inappropriate platelet activation plays a role in venous thrombosis, such that platelet inhibitors can be BACKGROUND OF THE INVENTION useful for the treatment or prevention of disorders associated with such thromboses. 0002 1. Field of the Invention 0009. A connection is emerging between platelet activa 0003. The present invention generally relates to the field of tion and inflammation, particularly allergic inflammation medicinal chemistry. More specifically, the present invention (e.g., in asthma) and inflammation at the sites of atheroscle relates to the use of synthetic carotenoid analogs, derivatives rotic damage. Therefore, compounds that inhibit platelet acti and compositions made using same for the treatment and vation can also be useful in the treatment or prevention of prevention of platelet aggregation and thrombus formation in disorders involving inflammation. a subject. 0010. There are a number of agents presently available 0004 2. Description of the Relevant Art that target platelet function. For example, aspirin is a rela 0005 Platelet accumulation at sites of vascular injury is a tively weak platelet inhibitor. However, aspirin can cause dynamic process that mediates formation of both the primary life-threatening allergic reactions in sensitive individuals. hemostatic plug and pathologic thrombus formation. The 0011. Another platelet inhibiting agent is ticlopidine mechanisms by which platelet surface proteins direct platelet (TICLIDTM, Roche Pharmaceuticals). Because it requires the recruitment to thrombi under flow conditions have been stud production of active metabolites to be effective, the effect of ied in detail. In addition to directing initial platelet adhesion, ticlopidine is delayed 24-48 hours. The drug can also cause cell-surface receptor interactions activate intracellular signal thrombotic thrombocytopenic purpura, a life-threatening ing. Intracellular signaling stimulates the release of thrombo condition, as well as nausea, abdominal pain, dyspepsia, diar genic Substances from platelet granules. Signaling also medi rhea and skin rash. ates activation of the platelet integrin CfB (gpIb-IIIa) that (0012 Clodiprogel (PLAVIXTM, Bristol-Meyers Squibb/ facilitates firm adhesion of platelets to thrombi. Sanofi Pharmaceuticals) is another platelet inhibitor that 0006 Arterial thrombosis mediates tissue infarction in requires the generation of active metabolites for its therapeu coronary artery disease, cerebrovascular disease, and periph tic efficacy.
Load more

Recommended publications
  • Stroke Prevention in Chronic Kidney Disease Disclosures
    5/18/2020 Controversies: Stroke Prevention in Chronic Kidney Disease Wei Ling Lau, MD FASN FAHA FACP Assistant Professor, Nephrology University of California, Irvine Visiting Fellow at OptumLabsCOPY Disclosures • Prior or current research funding from NIH, AHA, Sanofi, ZS Pharma, and Hub Therapeutics. • Associate Medical Director for home peritoneal dialysis at Fresenius University Dialysis Center of Orange. • Has beenNOT on Fresenius medical advisory board for Velphoro. • No conflicts of interest relevant to the current talk. Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 1 5/18/2020 Stroke Prevention in CKD • Blood pressure targets • Antiplatelet agents • Statins • Anticoagulation Controversies: Stroke prevention in CKD Wei Ling Lau, MD COPY BP TARGETS Data is limited, as patients with CKD were historically excluded from clinical trials NOT Whelton 2017 ACC/AHA hypertension guidelines [Hypertension 2018] Controversies: Stroke prevention in CKD Wei Ling Lau, MD DO 2 5/18/2020 Systolic Blood Pressure Intervention Trial SPRINT: BP lowering to <120 vs <140 mmHg significantly lowered rate of CVD composite primary outcome; no clear effect on stroke Controversies: Stroke prevention in CKD The SPRINT Research Group. N Engl J Med 2015 p2103 Wei Ling Lau, MD COPY SPRINT subgroup analysis: CKD • Patients with CKD stage 3‐4 (eGFR of 20 to <60) comprised 28% of the SPRINT study population • Intensive BP management seemed to provide the same benefits for reduction in the CVD composite primary outcomeNOT – but did not impact stroke Controversies: Stroke prevention in CKD Cheung 2017 J Am Soc Nephrol p2812 Wei Ling Lau, MD DO 3 5/18/2020 The hazard of incident stroke associated with systolic BP (SBP) and chronic kidney disease (CKD)BP using and an unadjusted stroke model risk: that contained J‐shaped dummy variables association for CKD and BP groups (A) and a fully adjusted model that contained dummy variables for CKD and BP grou..
    [Show full text]
  • Toward an in Vitro Bioequivalence Test
    TOWARD AN IN VITRO BIOEQUIVALENCE TEST by Jie Sheng A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmaceutical Sciences) In The University of Michigan 2007 Doctoral Committee: Professor Gordon L. Amidon, Chair Professor Henry Y. Wang Associate Professor Nair Rodriguez-Hornedo Associate Professor Steven P. Schwendeman Jie Sheng © 2007 All Rights Reserved To Kurt Q. Zhu, my husband and my very best friend, and to Diana S. Zhu and Brandon D. Zhu, my lovely children. ii Acknowledgements Most of all, I thank Prof. Gordon L. Amidon, for his support, guidance, and inspiration during my graduate studies at the University of Michigan. Being his student is the best step happened in my career. I am always amazed by his vision, energy, patience and dedication to the research and his students. He trained me to grow as a scientist and as a person. I also wish to thank all of my committee members, Professors David Fleisher, Nair Rodriguez-Hornedo, Steven Schwendeman and Henry Wang, for their very insightful and constructive suggestions to my research. It took all their efforts to raise me as a professional scientist in pharmaceutical field. They all contributed significantly to development and improvement of my graduate work. Especially, Prof. Wang has also guided me in thinking of career development as if 20-year later. I felt to be his student in many ways. I thank mentors, colleagues and friends, Prof. John Yu from Ohio State University, Paul Sirois from Eli Lilly, Kurt Seefeldt, Chet Provoda, Jonathan Miller, John Chung, Chris Landoswki, Haili Ping and Yasuhiro Tsume from College of Pharmacy, for many interesting discussions throughout the graduate program.
    [Show full text]
  • CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene and Pathophysiological Conditions
    Review CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene and Pathophysiological Conditions Rossana Roncato 1,*,†, Jacopo Angelini 2,†, Arianna Pani 2,3,†, Erika Cecchin 1, Andrea Sartore-Bianchi 2,4, Salvatore Siena 2,4, Elena De Mattia 1, Francesco Scaglione 2,3,‡ and Giuseppe Toffoli 1,‡ 1 1 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, 33081 Aviano, Italy; [email protected] (E.C.); [email protected] (E.D.M.); [email protected] (G.T.) 2 Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122 Milan, Italy; [email protected] (J.A.); [email protected] (A.P.); [email protected] (A.S-B.); [email protected] (S.S.); [email protected] (F.S.) 3 Clinical Pharmacology Unit, ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore 3, 20162 Milan, Italy 4 Department of Hematology and Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy * Correspondence: [email protected]; Tel.:+390434659130 † These authors contributed equally. ‡ These authors share senior authorship. Int. J. Mol. Sci. 2020, 21, x; doi: www.mdpi.com/journal/ijms Int. J. Mol. Sci. 2020, 21, x 2 of 8 Table S1. Co-administered agents categorized according to their potential risk for Drug-Drug interaction (DDI) in combination with CDK4/6 inhibitors (CDKis). Colors suggest the risk of DDI with CDKis: green, low risk DDI; orange, moderate risk DDI; red, high risk DDI. ADME, absorption, distribution, metabolism, and excretion; GI, Gastrointestinal; TdP, Torsades de Pointes; NTI, narrow therapeutic index. * Cardiological toxicity should be considered especially for ribociclib due to the QT prolongation.
    [Show full text]
  • Salts of Menantine and Cox-Inhibitors and Their Crystal Form in The
    (19) & (11) EP 2 098 500 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.09.2009 Bulletin 2009/37 C07C 57/40 (2006.01) C07C 63/70 (2006.01) C07C 65/01 (2006.01) C07C 211/38 (2006.01) (2006.01) (2006.01) (21) Application number: 08384002.5 A61K 31/13 A61K 31/192 A61P 25/02 (2006.01) A61P 29/00 (2006.01) (2006.01) (22) Date of filing: 07.03.2008 A61P 25/28 (84) Designated Contracting States: • Tesson, Nicolas AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 08028 Barcelona (ES) HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT • Farran, Joan RO SE SI SK TR 08028 Barcelona (ES) Designated Extension States: • Rafecas, Llorenc AL BA MK RS 08028 Barcelona (ES) (71) Applicant: Laboratorios Del. Dr. Esteve, S.A. (74) Representative: Peters, Hajo et al 08041 Barcelona (ES) Graf von Stosch Patentanwaltsgesellschaft mbH (72) Inventors: Prinzregentenstrasse 22 • Buschmann, Helmut, Heinrich, Dr. 80538 München (DE) 52076 Aachen (Walheim) (DE) (54) Salts of menantine and cox-inhibitors and their crystal form in the treatment of pain (57) The present invention relates to salts of Memantine and COX-INHIBITORs, their crystal form, the processes for preparation of the same and their uses as medicaments, more particularly for the treatment of pain. EP 2 098 500 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 098 500 A1 Description [0001] The present invention relates to salts of Memantine and COX-INHIBITORs, their crystal from, and their specific polymorphs, the processes for preparation of the same and their uses as medicaments, more particularly for the treatment 5 of pain.
    [Show full text]
  • Antithrombotic Treatment After Stroke Due to Intracerebral Haemorrhage (Review)
    Cochrane Database of Systematic Reviews Antithrombotic treatment after stroke due to intracerebral haemorrhage (Review) Perry LA, Berge E, Bowditch J, Forfang E, Rønning OM, Hankey GJ, Villanueva E, Al-Shahi Salman R Perry LA, Berge E, Bowditch J, Forfang E, Rønning OM, Hankey GJ, Villanueva E, Al-Shahi Salman R. Antithrombotic treatment after stroke due to intracerebral haemorrhage. Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No.: CD012144. DOI: 10.1002/14651858.CD012144.pub2. www.cochranelibrary.com Antithrombotic treatment after stroke due to intracerebral haemorrhage (Review) Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 5 OBJECTIVES ..................................... 5 METHODS ...................................... 6 RESULTS....................................... 8 Figure1. ..................................... 9 Figure2. ..................................... 11 Figure3. ..................................... 12 DISCUSSION ..................................... 14 AUTHORS’CONCLUSIONS . 15 ACKNOWLEDGEMENTS . 15 REFERENCES ..................................... 15 CHARACTERISTICSOFSTUDIES . 18 DATAANDANALYSES. 31 Analysis 1.2. Comparison 1 Short-term antithrombotic treatment, Outcome 2 Death. 31 Analysis 1.6. Comparison 1 Short-term antithrombotic
    [Show full text]
  • Antiplatelet Regimens in the Long-Term Secondary Prevention of Transient Ischaemic Attack and Ischaemic Stroke: an Updated Network Meta-Analysis
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2015-009013 on 17 March 2016. Downloaded from Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis Peng-Peng Niu, Zhen-Ni Guo, Hang Jin, Ying-Qi Xing, Yi Yang To cite: Niu P-P, Guo Z-N, ABSTRACT et al Strengths and limitations of this study Jin H, . Antiplatelet Objective: To examine the comparative efficacy and regimens in the long-term safety of different antiplatelet regimens in patients with ▪ secondary prevention of Since the dose of aspirin ranged from 30 to prior non-cardioembolic ischaemic stroke or transient transient ischaemic attack 1500 mg daily, treatment with aspirin was and ischaemic stroke: an ischaemic attack. divided into four different regimens and treat- updated network meta- Design: Systematic review and network meta-analysis. ment with aspirin plus dipyridamole was divided analysis. BMJ Open 2016;6: Data sources: As on 31 March 2015, all randomised into two different regimens. e009013. doi:10.1136/ controlled trials that investigated the effects of ▪ Duration of follow-up was included in the model bmjopen-2015-009013 antiplatelet agents in the long-term (≥3 months) to perform the network meta-analysis. secondary prevention of non-cardioembolic transient ▪ Estimates from sensitivity analyses were compat- ▸ Prepublication history and ischaemic attack or ischaemic stroke were searched ible with the main analysis, except that cilostazol additional material is and identified. was not significantly more effective than clopido- available. To view please visit Outcome measures: The primary outcome measure grel and triflusal in preventing serious vascular the journal (http://dx.doi.org/ of efficacy was serious vascular events (non-fatal events when setting the prior on the variance 10.1136/bmjopen-2015- stroke, non-fatal myocardial infarction and vascular equal to a uniform (0, 1000).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Digital Ischemic Events Related to Gemcitabine: Report of Two Cases and a Systematic Review
    257 case report Digital ischemic events related to gemcitabine: Report of two cases and a systematic review Cvetka Grasic Kuhar, Tanja Mesti, Branko Zakotnik Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia Received 1 February 2010 Accepted 1 March 2010 Correspondence to: Cvetka Grasič Kuhar, MD. PhD, Department of Medical Oncology, Institute of Oncology Ljubljana, Zaloška c. 2, SI-1000 Ljubljana, Slovenia; Phone: +386 1 5879282; Fax: +386 1 5879305; E-mail: [email protected] Disclosure: No potential conflicts of interest were disclosed. Background. Gemcitabine is a potent cytotoxic agent used in the treatment of many solid tumours, sarcomas and lymphomas. Vascular toxicity and thrombotic events related to gemcitabine seem to be underreported. Case report. We report two cases of gemcitabine related digital ischemic events. Case 1. A 65-year-old man was given the first-line treatment with gemcitabine for the advanced adenocarcinoma of pancreas. After four weekly doses of gemcitabine (total dose 4000 mg/m2) he presented with Raynaud’s like phenom- enon and ischemic fingertips necrosis in five digits of both hands. Symptoms resolved in all but one digit after stopping chemotherapy and treatment with iloprost trometamol infusion. Case 2. A 77-year-old man, ex-smoker, was administered a combination of gemcitabine and cisplatin as the first-line treatment for the locally advanced bladder cancer. After 4 cycles of the treatment (total dose of gemcitabine 4000 mg/m2) the patient suffered digital ischemia and necrosis on two digits of a right leg. Arteriography revealed preex- isting peripheral arterial occlusive disease (PAOD) of both legs with very good peripheral collateral circulation and absent microcirculation of affected two digits.
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity
    Journal of Personalized Medicine Article Use of Antiplatelet Agents Decreases the Positive Predictive Value of Fecal Immunochemical Tests for Colorectal Cancer but Does Not Affect Their Sensitivity Yoonsuk Jung 1,† , Eui Im 2,†, Jinhee Lee 3, Hyeah Lee 4 and Changmo Moon 5,6,* 1 Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea; [email protected] 2 Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine and Cardiovascular Center, Yongin Severance Hospital, Yongin 16995, Korea; [email protected] 3 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon 16499, Korea; [email protected] 4 Clinical Trial Center, Ewha Womans University Mokdong Hospital, Seoul 07985, Korea; [email protected] 5 Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul 07985, Korea 6 Inflammation-Cancer Microenvironment Research Center, Ewha Womans University, Seoul 07804, Korea * Correspondence: [email protected]; Tel.: +82-2-2650-2945; Fax: +82-2-2650-5936 † These authors contributed equally to this study. Abstract: Previous studies have evaluated the effects of antithrombotic agents on the performance of fecal immunochemical tests (FITs) for the detection of colorectal cancer (CRC), but the results were inconsistent and based on small sample sizes. We studied this topic using a large-scale population- based database. Using the Korean National Cancer Screening Program Database, we compared Citation: Jung, Y.; Im, E.; Lee, J.; Lee, the performance of FITs for CRC detection between users and non-users of antiplatelet agents and H.; Moon, C. Use of Antiplatelet warfarin.
    [Show full text]